Here's What Key Metrics Tell Us About Jazz (JAZZ) Q1 Earnings

Jazz Pharmaceuticals (JAZZ) reported $897.84 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 0.5$1.68 for the same period compares to $2.68 a year ago.The reported revenue represents a surprise of -8.52$981.41 million. With the consensus EPS estimate being $4.51, the EPS surprise was -62.75%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...